#USA #Lund #Clinical Development #TFS HealthScience #Miriam Martin

TFS HealthScience Welcomes Miriam Martin as Vice President of Business Development

TFS HealthScience, a globally recognized contract research organization (CRO), has officially announced the appointment of Miriam Martin to the position of Vice President of Business Development within its Clinical Development Services (CDS) division. With over 15 years of experience at TFS, Miriam has been a pivotal figure in the company, showcasing her leadership skills through various roles that have significantly contributed to its financial success.

Miriam's deep industry knowledge, which spans both sponsors and CROs, positions her perfectly to lead TFS into a new chapter marked by strategic growth and operational excellence. Her promotion to the executive committee signifies the company’s commitment to fostering strong partnerships and driving innovation.

During her tenure, Miriam has played a crucial role in navigating TFS through an era characterized by five acquisitions and an integration within the Ratos Group, alongside a global expansion strategy aimed at key markets in North America, Europe, the Asia-Pacific region, and the Middle East. Her leadership has been instrumental in elevating sales performance and enhancing the essential business development functions within the organization.

“Miriam's influence on TFS is both profound and lasting,” said Markus Granlund, CEO of TFS HealthScience. “She has helped shape TFS into what it is today. Her leadership, insights, and relentless dedication to our mission make her the ideal fit for this role. We are proud to welcome her to the executive committee.”

Miriam’s appointment comes at a time when TFS is experiencing sustained momentum, bolstered by advancements in key therapeutic areas. Recently, the company initiated pivotal clinical programs in both early and late phases within ophthalmology, addressing significant conditions such as diabetic macular edema and other retinal disorders. In oncology, TFS is expanding its efforts in pancreatic cancer, non-small cell lung cancer, and various hematological indications.

Furthermore, TFS is enhancing its portfolios in dermatology and neuroscience, having recently initiated studies in atopic dermatitis, complex wound healing, and multiple sclerosis. These advancements underscore the company’s extensive therapeutic expertise and its unwavering commitment to scientific excellence and patient-centered impact.

“I am incredibly honored to grow alongside TFS in this role,” remarked Miriam Martin. “TFS has invested in me and surrounded me with remarkable people. I am grateful for the support I've received and excited to continue working towards our goal of empowering our partners and enriching lives.”

As the new Vice President of Business Development in CDS, Miriam will focus on enhancing client engagement, enabling sustainable growth strategies, and fostering innovative approaches in clinical development. Her role on the executive committee will also provide her with greater opportunities to advocate for TFS partners, collaborate across functions, and further reinforce an inclusive culture prioritizing relationships, innovation, and shared successes.

About TFS HealthScience

TFS HealthScience is a leading global contract research organization (CRO) collaborating with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With a presence in 40 countries, TFS and its strategic partners offer tailored solutions for strategic sourcing and clinical development in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. TFS is committed to empowering partners and enriching lives, providing flexible solutions that blend global reach with the agility and responsiveness of a mid-sized CRO.

For more information, visit www.tfscro.com.